AbbVie
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IE
US
US
US
US
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Track AbbVie in real time with a live news feed covering AbbVie stock news, official press releases, company announcements, and an archive of historical AbbVie news. ...more
Loading news...
Loading more...
10:47 AM | Friday | Nov 13, 2026
Sign in to download news snippet
Treasuries now pay 5.1% with zero equity risk, so dividend stocks have to earn their place in an income portfolio. Five payers pass a stricter test than yield alone, and one of them yields barely half the Treasury rate.
Read full articleNo data available for this time period.
Change the time range to see results.
Treasuries now pay 5.1% with zero equity risk, so dividend stocks have to earn their place in an income portfolio. Five payers pass a stricter test than yield alone, and one of them yields barely half the Treasury rate.
Read full articleWith stocks arguably priced like it's 1999, these three dividend payers could help you weather what comes next.
Read full article
Market volatility is unpleasant, but it's important that investors don't force themselves into a false choice between safety and growth. Over the last two years, technology stocks, particularly AI stocks, have driven strong portfolio gains for active and passive investors.
Read full article
AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges.
Read full article
AlphaCore Capital LLC grew its stake in AbbVie Inc. (NYSE: ABBV) by 11.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,568 shares of the company's stock after acquiring an additional 5,092 shares during the period. AlphaCore Capital LLC's
Read full article
CenterBook Partners LP acquired a new stake in AbbVie Inc. (NYSE: ABBV) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 7,216 shares of the company's stock, valued at approximately $1,888,000. A number of other hedge funds have also added to
Read full article
– HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported statistically significant improvements in satisfaction with facial appearance and skin quality following a treatment regimen that also included skincare – Interim results from HALO, a Phase 4 study of hyaluronic acid (HA) injectables in adults on GLP-1 medications, showed high patient satisfaction, with 95.7% of participants satisfied or very satisfied that they still looked like themselves – The findings are part of a broad Allergan Aesthetics scientific program at ASDS 2026, advancing research across medical weight loss, multimodal treatment, neurotoxin innovation and skin quality IRVINE, Calif.
Read full article
Quitting at 58 sounds simple when your savings sit in a Roth. But one hidden clock, and the wrong conversion pulled at the wrong time, can turn tax-free money into a penalty bill. Find out which dates to check before you walk out.
Read full article
Six household-name dividend payers hand you a steady paycheck, but one of them gets taxed far harder than the other five. Find out which holding belongs in a Roth first, and how the bill snowballs over two decades.
Read full article
A fat yield means nothing if the check bounces. Five payers across telecom, tobacco, pharma, real estate and pipelines show how to test coverage, and one of them carries a debt pile that could threaten its raise streak.
Read full article
No data available for this time period.
Change the time range to see results.